Fact-checked by Grok 2 weeks ago

Dromotropic

In pharmacology and physiology, a dromotropic effect refers to the influence of agents or stimuli on the conduction velocity of electrical impulses through the heart's specialized conductive tissues, particularly the atrioventricular (AV) node, which coordinates atrial and ventricular contractions.^[1] This property is distinct from chronotropic (heart rate) and inotropic (contractility) effects, focusing instead on the speed and efficiency of impulse transmission to prevent arrhythmias and ensure synchronized cardiac function.^[2] Dromotropic effects are classified as positive or negative based on whether they accelerate or decelerate conduction. Positive dromotropic effects enhance AV node conduction velocity, primarily through sympathetic nervous system stimulation via β1-adrenergic receptors, as seen with catecholamines like norepinephrine, which activate L-type calcium channels to facilitate faster impulse propagation.^[1] In contrast, negative dromotropic effects slow conduction, often mediated by parasympathetic activation via M2 muscarinic receptors and acetylcholine, which prolongs AV nodal delay by increasing potassium currents such as IKACh.^[1] Clinically, dromotropic agents play a key role in managing cardiac arrhythmias, such as supraventricular tachycardia. Negative dromotropic drugs, including calcium channel blockers like verapamil and diltiazem, as well as digoxin and adenosine, are used to depress AV nodal conduction and control ventricular rates in conditions like atrial fibrillation.^[3] These effects are modulated by the autonomic nervous system, with therapeutic applications requiring careful monitoring to avoid excessive slowing that could lead to heart block.^[4]

Definition and Background

Definition

Dromotropic refers to the physiological effect that modulates the velocity of electrical impulse conduction through the heart's specialized conduction pathways, particularly the atrioventricular (AV) node, where impulses are typically delayed to allow atrial contraction before ventricular activation.^[5] This modulation can accelerate or decelerate conduction speed, influencing the timing of ventricular depolarization without primarily altering other cardiac parameters.^[6] In contrast to chronotropic effects, which adjust heart rate by acting on the sinoatrial node's pacemaker activity, or inotropic effects, which change the force of myocardial contraction, dromotropic effects specifically target conduction velocity to affect impulse propagation, potentially leading to changes in atrioventricular synchrony.^[5] Positive dromotropy enhances conduction speed, while negative dromotropy slows it, often via autonomic nervous system influences or pharmacological agents.^[2] The term "dromotropic" was introduced in 1897 by German physiologist Theodor Wilhelm Engelmann in his seminal paper on the myogenic origin of heart activity and automatic excitability in peripheral nerve fibers.^[7]

Etymology

The term "dromotropic" derives from the Greek "dromos" (δρόμος), meaning "running," "course," or "race," combined with the suffix "-tropic," from "tropos" (τρόπος), denoting "turning" or "affecting." This etymological structure reflects an influence on the pathway or velocity of signal transmission, particularly in physiological contexts like nerve or muscle conduction.^[8]^[9] The adjective "dromotropic" first appeared in scientific literature in the 1890s, with its earliest documented use in 1895–1897 by German physiologist Theodor Wilhelm Engelmann in studies on frog heart innervation. Engelmann coined the term alongside related descriptors—chronotropic (affecting rate or timing), inotropic (affecting contractility), and bathmotropic (affecting excitability)—to classify the distinct actions of cardiac nerves on heart function.80106-9/fulltext)^[10] Within autonomic pharmacology, "dromotropic" evolved as part of this "-tropic" nomenclature family, standardizing descriptions of sympathetic and parasympathetic effects on cardiac electrophysiology. This framework, originating from Engelmann's work, persists in modern terminology to denote agents or stimuli modulating conduction speed without altering rate or force directly.^[11]

Physiological Role

Cardiac Conduction System Basics

The cardiac conduction system is a specialized network of modified cardiac muscle cells that generates electrical impulses and coordinates the sequential contraction of the heart's chambers to ensure efficient blood flow. This system includes four primary components: the sinoatrial (SA) node, atrioventricular (AV) node, bundle of His, and Purkinje fibers, each with distinct anatomical locations and roles in impulse initiation and propagation. The SA node, situated in the upper wall of the right atrium near the entrance of the superior vena cava, serves as the heart's primary pacemaker by spontaneously generating action potentials at a rate of 60 to 100 beats per minute under normal conditions. These impulses rapidly spread through the atrial myocardium, causing atrial contraction.^[12]^[13] The electrical impulse then reaches the AV node, located near the center of the heart at the junction of the atria and ventricles, where conduction slows significantly to allow complete atrial emptying before ventricular activation. This AV nodal delay lasts approximately 0.1 seconds (100 milliseconds), preventing premature ventricular contraction and optimizing cardiac output. From the AV node, the impulse travels via the bundle of His—a collection of fibers extending along the interventricular septum—to the left and right bundle branches, which distribute the signal to the ventricular walls. The Purkinje fibers, branching extensively within the endocardium of the ventricles, enable rapid and synchronized depolarization of the ventricular myocardium, ensuring a coordinated "bottom-up" contraction that efficiently pumps blood to the body and lungs. Overall, the impulse travels from the atria to the ventricles in approximately 0.1 to 0.2 seconds, as reflected in the normal PR interval on an electrocardiogram.^[14]^[15]^[12] At the electrophysiological level, conduction within the cardiac system relies on action potentials generated by voltage-gated ion channels in specialized cells, which vary in speed across components due to differences in channel types and densities. In non-pacemaker cells like those in the atria, ventricles, and Purkinje fibers (fast-response cells), the action potential consists of five phases: phase 0 involves rapid depolarization driven by influx of sodium ions (Na⁺) through fast voltage-gated Na⁺ channels, achieving conduction velocities up to 4 meters per second in Purkinje fibers; phase 1 is a brief early repolarization from transient potassium (K⁺) efflux; phase 2 maintains a prolonged plateau via calcium (Ca²⁺) influx through L-type Ca²⁺ channels balanced against K⁺ efflux; phase 3 completes repolarization through dominant K⁺ efflux; and phase 4 maintains a stable resting potential around -90 mV primarily due to high K⁺ conductance. In contrast, slow-response cells in the SA and AV nodes rely more on Ca²⁺ channels for phase 0 depolarization, resulting in slower conduction (about 0.05 to 0.5 meters per second) and the characteristic delays essential for timed contractions; phase 4 in these pacemaker cells features spontaneous depolarization via "funny" currents (I_f, involving slow Na⁺ influx) and T-type Ca²⁺ channels, setting the rhythm. These ion channel dynamics underpin the variable conduction speeds that synchronize heart function, with dromotropic effects modulating them through autonomic influences.^[16]^[14]^[17]

Mechanism of Dromotropic Effects

Dromotropic effects refer to modifications in the velocity of electrical impulse conduction through the cardiac conduction system, primarily influencing the atrioventricular (AV) node and His-Purkinje system. Positive dromotropic effects accelerate conduction, particularly by shortening the refractory period and AV nodal delay, thereby facilitating faster propagation of impulses from atria to ventricles.^[1] In contrast, negative dromotropic effects decelerate conduction, prolonging the AV delay and potentially leading to incomplete or blocked impulses at the AV node.^[1] The AV node exhibits slow conduction velocity due to its reliance on L-type calcium channels for phase 0 depolarization of the action potential, where calcium influx (supplemented by some sodium through slow channels) drives the upstroke. Negative dromotropic effects slow AV nodal conduction by reducing L-type calcium channel activity, which diminishes inward calcium current and prolongs the action potential duration.^[18] Conversely, in the His-Purkinje system, fast conduction is mediated by voltage-gated fast sodium channels responsible for rapid phase 0 depolarization; acceleration here occurs through enhanced sodium channel availability or function, increasing overall ventricular activation speed. Autonomic nervous system modulation plays a central role in these effects. Sympathetic stimulation via β1-adrenergic receptors activates adenylyl cyclase, elevating cyclic AMP (cAMP) levels and activating protein kinase A (PKA), which phosphorylates L-type calcium channels in the AV node to enhance calcium influx and thereby increase conduction velocity (positive dromotropy).^[1] Parasympathetic (vagal) stimulation, mediated by acetylcholine binding to M2 muscarinic receptors, couples to inhibitory G-proteins that decrease cAMP, inhibit PKA, and activate acetylcholine-sensitive potassium channels (K_ACh), leading to membrane hyperpolarization and reduced excitability, which slows AV nodal conduction (negative dromotropy).^[1] These autonomic influences ensure adaptive regulation of conduction in response to physiological demands.^[19]

Pharmacological and Clinical Aspects

Positive Dromotropic Agents

Positive dromotropic agents are pharmacological substances that accelerate the velocity of electrical impulse conduction within the cardiac conduction system, primarily by enhancing atrioventricular (AV) nodal transmission.^[20] These agents counteract excessive vagal tone or stimulate sympathetic pathways to improve conduction efficiency, which is crucial in conditions involving slowed heart rhythms.^[21] Sympathomimetic agents such as isoproterenol exemplify positive dromotropic effects through beta-1 adrenergic receptor agonism, which increases calcium influx and shortens the A-H interval (a measure of AV nodal conduction time) in isolated heart preparations.^[22] Isoproterenol reduces AV nodal delay by facilitating faster impulse propagation across the node, thereby enhancing overall cardiac excitability.^[22] Similarly, atropine exerts a positive dromotropic action via competitive muscarinic receptor blockade, diminishing parasympathetic inhibition on the AV node and thereby accelerating conduction velocity.^[23] This blockade reduces vagally mediated delays in AV transmission, promoting more rapid sinoatrial to ventricular signal relay.^[21] Endogenous catecholamines, including epinephrine and norepinephrine, play a key role in positive dromotropy during acute stress responses. Released from the adrenal medulla and sympathetic nerve endings, these agents activate beta-1 receptors to elevate conduction speed, ensuring synchronized cardiac output under physiological demands like fight-or-flight scenarios.^[20] Their effects integrate with broader sympathetic activation to maintain efficient AV nodal function amid heightened adrenergic tone.^[4] In therapeutic contexts, these agents are employed to manage bradyarrhythmias by restoring adequate conduction rates. For instance, intravenous atropine typically onset within 1-2 minutes, rapidly alleviating AV nodal blocks associated with vagal overactivity.^[21] Isoproterenol infusion similarly supports conduction in acute settings, though its use requires careful monitoring due to potent beta-adrenergic stimulation.^[24]

Negative Dromotropic Agents

Negative dromotropic agents are substances that decrease the velocity of electrical impulse conduction through the cardiac conduction system, primarily by prolonging the refractory period or slowing depolarization in specific tissues. Physiologically, increased vagal tone serves as a natural negative dromotrope, particularly during rest, where parasympathetic stimulation inhibits AV nodal conduction via acetylcholine-mediated hyperpolarization of nodal cells.^[25]^[23] Among pharmacological agents, non-dihydropyridine calcium channel blockers such as verapamil and diltiazem exemplify negative dromotropic effects by selectively inhibiting L-type calcium channels in the AV node, thereby reducing the slow inward calcium current essential for nodal depolarization. This action prolongs the AV nodal refractory period, slowing conduction and preventing rapid impulse transmission from atria to ventricles.^[26]^[27] Digoxin exerts negative dromotropic effects primarily by enhancing parasympathetic (vagal) tone on the AV node, which slows conduction velocity and prolongs the refractory period.^[28] Adenosine produces a potent, transient negative dromotropic effect by activating A1 adenosine receptors in the AV node, leading to hyperpolarization and temporary blockade of conduction.^[29] Class I antiarrhythmics, including flecainide, exert negative dromotropic influence on the His-Purkinje system through use-dependent blockade of voltage-gated sodium channels, which markedly slows conduction velocity in fast-response Purkinje fibers and prolongs the HV interval.^[30]^[31] Beta-blockers like propranolol, a non-selective agent, contribute to negative dromotropy by antagonizing β-adrenergic receptors, thereby reducing sympathetic enhancement of nodal and His-Purkinje conduction and slowing impulse propagation.^[32]^[33] In opposition to positive dromotropic agents that accelerate conduction, these negative agents are crucial for modulating excessive impulse transmission in various cardiac conditions.

Clinical Significance

Role in Arrhythmias

Dromotropic imbalances play a critical role in the pathogenesis of atrioventricular (AV) blocks, where negative dromotropy slows conduction through the AV node, leading to delayed or blocked impulse transmission. In first-degree AV block, conduction delay manifests as a prolonged PR interval exceeding 200 ms on electrocardiogram (ECG), resulting from impaired AV nodal propagation due to factors exerting negative dromotropic effects.^[34]^[35] This prolongation reflects a subtle but consistent slowing of atrial-to-ventricular impulse conduction, often without symptoms but serving as an early indicator of dromotropic dysfunction.^[36] More severe negative dromotropy can progress to second-degree AV block, characterized by intermittent failure of atrial impulses to conduct to the ventricles, as seen in Mobitz type I (Wenckebach) where progressive PR interval lengthening culminates in a dropped beat. Adenosine, for instance, induces this block by slowing AV nodal recovery of excitability, creating discontinuous propagation across junctional tissues.^[18] In third-degree (complete) AV block, extreme negative dromotropic effects cause total dissociation between atrial and ventricular rhythms, with no conduction through the AV node, leading to independent ventricular escape rhythms. Agents like diazepam can precipitate this by gradually prolonging the PR interval until complete block occurs.^[37] Conversely, in tachyarrhythmias such as those associated with Wolff-Parkinson-White (WPW) syndrome, enhanced dromotropy via accessory pathways facilitates rapid conduction that bypasses the normal AV nodal delay, predisposing to re-entrant circuits and supraventricular tachycardias. These pathways allow early ventricular activation, shortening the PR interval to less than 120 ms on ECG and producing a delta wave, which indicates accelerated atrioventricular transmission.^[36]^[38] This abnormal fast conduction enables atrial impulses to reach the ventricles prematurely, increasing the risk of rapid ventricular rates during atrial fibrillation.^[38] ECG assessment of PR interval variations provides key diagnostic metrics for dromotropic dysfunction in arrhythmias; prolongation signals negative effects in AV blocks, while shortening highlights enhanced conduction in pre-excitation syndromes like WPW. These changes directly correlate with conduction velocity alterations, aiding in the identification of underlying dromotropic imbalances without invasive testing in many cases.^[34]^[36]

Therapeutic and Diagnostic Applications

Dromotropic modulation plays a key role in managing cardiac rhythm disorders through pharmacological interventions that alter atrioventricular (AV) nodal conduction velocity. Negative dromotropic agents, such as calcium channel blockers like verapamil, are commonly employed for rate control in atrial fibrillation (AF) by slowing AV nodal conduction and reducing ventricular response rates. For instance, intravenous verapamil effectively controls heart rates in most patients with AF, achieving significant reductions in ventricular rates, often by 20-40% from baseline rapid rates exceeding 120 beats per minute.^[39] Beta-blockers and digoxin also serve as negative dromotropic options for similar purposes in AF, helping to prevent tachycardia-induced cardiomyopathy by maintaining controlled ventricular rates.^[40] Positive dromotropic agents are utilized to treat symptomatic bradycardia by enhancing AV nodal conduction. Atropine, a vagolytic agent, is a first-line pharmacological option in advanced cardiac life support protocols for bradydysrhythmias, increasing conduction velocity through parasympathetic inhibition.^[41] Isoproterenol, a beta-adrenergic agonist, provides positive dromotropic effects by stimulating AV nodal pathways, making it suitable for temporary management of bradycardia unresponsive to atropine, with dosing titrated to achieve desired heart rates.^[24] In cases refractory to pharmacological therapy, invasive procedures target dromotropic pathways directly. AV nodal ablation is a palliative strategy for drug-resistant AF, particularly in patients with heart failure, where it interrupts AV conduction to enforce rate control via subsequent pacemaker implantation, preferably using conduction system pacing techniques such as His-bundle or left bundle branch pacing to optimize synchrony and outcomes as of 2024, leading to improved symptoms, quality of life, and modest ejection fraction gains of 4-7% in those with systolic dysfunction.^[42]^[43] Pacemaker implantation is indicated for persistent bradycardia due to irreversible negative dromotropy or iatrogenic causes, such as drug-induced AV block, ensuring reliable ventricular pacing when pharmacological restoration fails.^[44] Diagnostic applications of dromotropic assessment involve electrophysiology studies (EPS) to evaluate AV nodal function precisely. During EPS, the AH interval—measuring conduction time from the atrium to the His bundle—quantifies AV nodal dromotropy, with prolongation or jumps exceeding 50 ms indicating dual pathways or conduction delays relevant to arrhythmias like AV nodal reentrant tachycardia.^[45] Catheter-based mapping in EPS guides targeted interventions by identifying sites of abnormal conduction velocity, aiding in the diagnosis of bradycardias and planning ablations.^[46]

References

[1]
Autonomic and endocrine control of cardiovascular function - PMC
Positive dromotropic effect (enhancement of conduction): Stimulation by the sympathetic nervous system also enhances the conductivity of the electrical signal.
[2]
Neural Regulation of Cardiac Rhythm - NCBI - NIH
Sep 21, 2022 · The autonomic nervous system (ANS) regulates cardiac function, including chronotropy, inotropy, lusitropy, and dromotropy.
[3]
Cardiovascular Drugs: Implications for Dental Practice Part 1
Dromotropic drugs influence conduction along neural conductive tissues. Drugs that decrease the speed of conduction through the cardiac neural conduction system ...
[4]
Dromotropic - an overview | ScienceDirect Topics
Dromotropic refers to the effect on the conduction speed of electrical impulses in the heart. AI generated definition based on: Clinical Cardio-Oncology, 2016.
[5]
Chapter 4 Autonomic Nervous System - Nursing Pharmacology - NCBI
Effects on the heart are described as having a positive chronotropic (increases heart rate), positive inotropic (increases force of contraction), and positive ...
[6]
Dromotropic - SkillStat
Refers to a physiological response that involves the conduction speed through the AV junction. Conducts the impulse through the fibrous plate that separates ...
[7]
Theodor Wilhelm Engelmann - PMC - NIH
Engelmann TW: Ueber den myogenen Ursprung der Herzthätigkeit und über automatische Erregbarkeit als normale Eigenschaft peripherischer Nervenfasern. Arch ...Missing: Herztätigkeit | Show results with:Herztätigkeit
[8]
dromotropic, adj. meanings, etymology and more | Oxford English ...
The earliest known use of the adjective dromotropic is in the 1890s. dromotropic is a borrowing from Greek. Etymons: Greek δρόμος, τροπικός.
[9]
dromotropic - Wiktionary, the free dictionary
Adjective. edit. dromotropic (not comparable). (physiology) Affecting the conductivity of cardiac muscle, used of the influence of cardiac nerves. Related ...<|control11|><|separator|>
[10]
Engelmann, Theodor Wilhelm | Encyclopedia.com
Engelmann was the first to distinguish the four types of activity of the heart nerves: isotropic, bathmotropic, chronotropic, and dromotropic (1896). This was ...
[11]
Myocardial Contractility: Historical and Contemporary Considerations
Mar 30, 2020 · This usage most likely evolved from the Germanic translation of the term sinew to mean vigor, strength, or power. The terms inotropy, inotropism ...Missing: first | Show results with:first
[12]
Heart Conduction System (Cardiac Conduction) - Cleveland Clinic
The bundle of His (sounds like “hiss”) is a branch of fibers (nerve cells) that extends from your AV node. This fiber bundle receives the electrical signal from ...
[13]
https://cvphysiology.com/arrhythmias/a002
[14]
Normal and Abnormal Electrical Conduction - CV Physiology
This leads to more rapid depolarization of adjacent cells, and more rapid conduction of action potentials (positive dromotropy). Sympathetic activation of the ...Missing: term | Show results with:term
[15]
Atrioventricular Node - an overview | ScienceDirect Topics
(3) After reaching the atrioventricular node (AV), there is a delay of approximately 100 ms that allows the atria to complete pumping blood before the impulse ...Missing: milliseconds | Show results with:milliseconds
[16]
Cardiac Action Potentials - CV Pharmacology
Action potential phases: · Phase 0: Depolarization - ↑ Ca++ and ↓ K+ conductance · Phase 3: Repolarization - ↑ K+ and ↓ Ca++ conductance · Phase 4: Spontaneous ...
[17]
Sinoatrial Node Action Potentials - CV Physiology
Phase 0 is the depolarization phase of the action potential. This is followed by phase 3 repolarization. Once the cell is completely repolarized at about -60 mV ...Missing: conduction | Show results with:conduction<|control11|><|separator|>
[18]
Cellular Basis for the Negative Dromotropic Effect of Adenosine on ...
The inward current responsible for the depolarization of AV nodal cells is carried by Ca2+ and Na+ ions through kinetically “slow” channels similar to those ...
[19]
Cardiac physiology - Knowledge @ AMBOSS
Sep 14, 2023 · Chronotropy: any influence on the heart rate ; Dromotropy: any influence on the conductivity of myocardium ; Inotropy: any influence on the force ...
[20]
Adrenergic and Cholinergic Receptors in the Heart - CV Physiology
When activated by a β1-agonist such as NE or EPI, heart rate is increased (positive chronotropy), conduction velocity is increased (positive dromotropy), ...
[21]
Atropine - StatPearls - NCBI Bookshelf - NIH
Jul 6, 2025 · Bradycardia: 1 mg every 3 to 5 minutes (3 mg max), repeat until obtaining desired heart rate, most effective for sinus and AV nodal disease.
[22]
role of nitric oxide, cGMP-dependent cAMP-phosphodiesterase and ...
Antagonism of the positive dromotropic effect of isoproterenol by adenosine: role of nitric oxide, cGMP-dependent cAMP-phosphodiesterase and protein kinase G.
[23]
Atropine (Muscarinic Receptor Antagonist) - CV Pharmacology
By hyperpolarizing the cells, vagal activation increases the cell's threshold for firing, which contributes to the reduction in firing rate. Similar ...Missing: dromotropic | Show results with:dromotropic
[24]
Isoproterenol - StatPearls - NCBI Bookshelf
Mechanism of Action ; Isoproterenol is a beta-1 and beta-2 adrenergic receptor agonist resulting in the following: Increased heart rate. Increased heart ...Continuing Education Activity · Indications · Mechanism of Action · AdministrationMissing: dromotropic | Show results with:dromotropic
[25]
Dromotropic - an overview | ScienceDirect Topics
Dromotropic refers to the effect on the rate of impulse conduction through the heart's conducting tissues, particularly influenced by autonomic nervous system ...
[26]
Calcium-Channel Blockers (CCBs) - CV Pharmacology
Approved calcium-channel blockers (CCBs) bind to L-type calcium channels on vascular smooth muscle, cardiac myocytes, and cardiac nodal tissue.Missing: dromotropic | Show results with:dromotropic
[27]
[PDF] Verapamil - accessdata.fda.gov
By inhibiting this influx, Verapamil slows AV conduction and prolongs the effective refractory period within the AV node in a rate-related manner. This ...
[28]
Electrophysiologic properties of flecainide acetate - ScienceDirect
The effect of the drug in slowing conduction within the His-Purkinje system is particularly marked and is commonly associated with prolongation of the HV ...
[29]
Flecainide - StatPearls - NCBI Bookshelf
Aug 8, 2023 · Flecainide prolongs depolarization and can slow conduction in the AV node and the His-Purkinje system. These changes can result in prolonged ...
[30]
Beta-blockers in cardiac arrhythmias–Clinical pharmacologist's point ...
It is important that beta-blockers are effective not only in the treatment of cardiac arrhythmias, but also in heart failure, being well-established alongside ...
[31]
Propranolol Monograph for Professionals - Drugs.com
Apr 10, 2024 · ... increases systolic ejection time and cardiac volume; decreases conduction velocity through the sinoatrial (SA) and atrioventricular (AV) ...
[32]
First-degree atrioventricular block in patients with atrial fibrillation ...
Jul 30, 2020 · PR interval prolongation > 200 ms resulting in the diagnosis of first-degree atrioventricular block (AVB1) is caused by a delay in the AV nodal/ ...
[33]
The effects of slow channel blockers and beta blockers on ... - PubMed
Beta blockers also have a negative dromotropic effect on the AV node. They prolong the AH interval and AV nodal refractory periods and may lengthen the PR ...
[34]
Wolff-Parkinson-White Syndrome - StatPearls - NCBI Bookshelf - NIH
This accessory pathway allows cardiac electrical activity to bypass the atrioventricular node conduction delay, and arrive early at the ventricle, leading ...
[35]
Negative dromotropic effect of diazepam on the AV node ... - PubMed
Negative dromotropic effect of diazepam on the AV node ... first to third degree AV blocks of longer duration following gradual prolongation of PR interval.Missing: prolonged | Show results with:prolonged
[36]
Wolff-Parkinson-White Syndrome and Accessory Pathways
Oct 12, 2010 · Some people are born with an extra piece of heart muscle tissue that connects directly between the atria and the ventricles, bypassing the AV node altogether.
[37]
Intravenous Verapamil for the Management of Atrial Fibrillation - NIH
Apr 12, 2025 · Conclusion. The intravenous administration of verapamil appears to be effective and safe for controlling the heart rate in most patients with AF ...
[38]
Rate control with intravenous diltiazem, verapamil, and metoprolol in ...
This study investigated the effect of intravenous diltiazem, metoprolol, and verapamil on rate control in patients with atrial fibrillation with rapid ...
[39]
ACLS Drugs for Bradycardia (2020)
There may be some action at the AV-node with atropine, but the effect will be negligible and typically not therapeutic. In most cases, atropine will not hurt ...
[40]
Atrioventricular Nodal Ablation in Atrial Fibrillation | Circulation
AVNA is a safe intervention that improves symptoms and QOL in patients with drug-refractory AF. Compared with pharmacotherapy alone, AVNA may be of particular ...
[41]
Cardiac Pacemakers (CAG-00063N) - Decision Memo - CMS
Medicare will continue to cover pacemaker implantation in patients with symptomatic bradycardia whether iatrogenic or induced by required pharmacologic therapy.
[42]
Electrophysiology Study and Ablation of Atrioventricular Nodal ...
Jul 30, 2023 · This activity reviews the role of electrophysiology study and catheter ablation in the diagnosis and treatment of AVNRT.
[43]
Electrophysiological Testing for the Investigation of Bradycardias
Mar 2, 2017 · In this article we review the role of electrophysiological testing in patients presenting with bradycardia due to sinus node or atrioventricular node disease.